{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:38:20Z","timestamp":1793907500318,"version":"4.8.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00415-026-13896-w","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T03:48:45Z","timestamp":1780285725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glial fibrillary acidic protein (GFAP) in biofluids: analytical considerations and clinical relevance in neurodegenerative diseases"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5912-9998","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Hanin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6867-8238","authenticated-orcid":false,"given":"Isabelle","family":"Quadrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5979-1033","authenticated-orcid":false,"given":"Jean-Louis","family":"Beaudeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-2935","authenticated-orcid":false,"given":"Foudil","family":"Lamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"13896_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L et al (2023) Hallmarks of neurodegenerative diseases. Cell 186:693\u2013714. https:\/\/doi.org\/10.1016\/j.cell.2022.12.032","journal-title":"Cell"},{"key":"13896_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020628","volume":"7","author":"H Phatnani","year":"2015","unstructured":"Phatnani H, Maniatis T (2015) Astrocytes in neurodegenerative disease. Cold Spring Harb Perspect Biol 7:a020628. https:\/\/doi.org\/10.1101\/cshperspect.a020628","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"13896_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","volume":"119","author":"MV Sofroniew","year":"2010","unstructured":"Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119:7\u201335. https:\/\/doi.org\/10.1007\/s00401-009-0619-8","journal-title":"Acta Neuropathol"},{"key":"13896_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41392-023-01628-9","volume":"8","author":"A Verkhratsky","year":"2023","unstructured":"Verkhratsky A, Butt A, Li B et al (2023) Astrocytes in human central nervous system diseases: a frontier for new therapies. Sig Transduct Target Ther 8:396. https:\/\/doi.org\/10.1038\/s41392-023-01628-9","journal-title":"Sig Transduct Target Ther"},{"key":"13896_CR5","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.12998\/wjcc.v11.i15.3385","volume":"11","author":"L Gradisnik","year":"2023","unstructured":"Gradisnik L, Velnar T (2023) Astrocytes in the central nervous system and their functions in health and disease: A review. World J Clin Cases. 11:3385\u20133394. https:\/\/doi.org\/10.12998\/wjcc.v11.i15.3385","journal-title":"World J Clin Cases."},{"key":"13896_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.tem.2024.08.001","volume":"36","author":"M Naveed","year":"2025","unstructured":"Naveed M, Smedlund K, Zhou Q-G et al (2025) Astrocyte involvement in metabolic regulation and disease. Trends Endocrinol Metab 36:219\u2013234. https:\/\/doi.org\/10.1016\/j.tem.2024.08.001","journal-title":"Trends Endocrinol Metab"},{"key":"13896_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.825816","volume":"12","author":"E Beard","year":"2021","unstructured":"Beard E, Lengacher S, Dias S et al (2021) Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives. Front Physiol 12:825816. https:\/\/doi.org\/10.3389\/fphys.2021.825816","journal-title":"Front Physiol"},{"key":"13896_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-023-06502-w","volume":"622","author":"R de Ceglia","year":"2023","unstructured":"de Ceglia R, Ledonne A, Litvin DG et al (2023) Specialized astrocytes mediate glutamatergic gliotransmission in the CNS. Nature 622:120\u2013129. https:\/\/doi.org\/10.1038\/s41586-023-06502-w","journal-title":"Nature"},{"key":"13896_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-3-319-08894-5_2","volume":"11","author":"A Schousboe","year":"2014","unstructured":"Schousboe A, Scafidi S, Bak LK et al (2014) Glutamate metabolism in the brain focusing on astrocytes. Adv Neurobiol 11:13\u201330. https:\/\/doi.org\/10.1007\/978-3-319-08894-5_2","journal-title":"Adv Neurobiol"},{"key":"13896_CR10","doi-asserted-by":"publisher","first-page":"eabo1997","DOI":"10.1126\/scitranslmed.abo1997","volume":"16","author":"B Zhu","year":"2024","unstructured":"Zhu B, Park J-M, Coffey SR et al (2024) Single-cell transcriptomic and proteomic analysis of parkinson\u2019s disease brains. Sci Transl Med 16:eabo1997. https:\/\/doi.org\/10.1126\/scitranslmed.abo1997","journal-title":"Sci Transl Med"},{"key":"13896_CR11","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1038\/s41593-024-01791-4","volume":"27","author":"A Serrano-Pozo","year":"2024","unstructured":"Serrano-Pozo A, Li H, Li Z et al (2024) Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer\u2019s disease. Nat Neurosci 27:2384\u20132400. https:\/\/doi.org\/10.1038\/s41593-024-01791-4","journal-title":"Nat Neurosci"},{"key":"13896_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1136398","author":"L-Y Fan","year":"2023","unstructured":"Fan L-Y, Yang J, Li M-L et al (2023) Single-nucleus transcriptional profiling uncovers the reprogrammed metabolism of astrocytes in Alzheimer\u2019s disease. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2023.1136398","journal-title":"Front Mol Neurosci"},{"key":"13896_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40478-020-0880-6","volume":"8","author":"O Al-Dalahmah","year":"2020","unstructured":"Al-Dalahmah O, Sosunov AA, Shaik A et al (2020) Single-nucleus RNA-seq identifies Huntington disease astrocyte states. Acta Neuropathol Commun 8:19. https:\/\/doi.org\/10.1186\/s40478-020-0880-6","journal-title":"Acta Neuropathol Commun"},{"key":"13896_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.37349\/ent.2023.00054","volume":"3","author":"JJ Miguel-Hidalgo","year":"2023","unstructured":"Miguel-Hidalgo JJ (2023) Neuroprotective astroglial response to neural damage and its relevance to affective disorders. Explor Neuroprot Ther. 3:328\u2013345. https:\/\/doi.org\/10.37349\/ent.2023.00054","journal-title":"Explor Neuroprot Ther."},{"key":"13896_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01394","volume":"11","author":"N D\u2019Ambrosi","year":"2020","unstructured":"D\u2019Ambrosi N, Apolloni S (2020) Fibrotic scar in neurodegenerative diseases. Front Immunol 11:1394. https:\/\/doi.org\/10.3389\/fimmu.2020.01394","journal-title":"Front Immunol"},{"key":"13896_CR16","doi-asserted-by":"publisher","first-page":"E3431","DOI":"10.1073\/pnas.1501835112","volume":"112","author":"T Sekiya","year":"2015","unstructured":"Sekiya T, Holley MC, Hashido K et al (2015) Cells transplanted onto the surface of the glial scar reveal hidden potential for functional neural regeneration. Proc Natl Acad Sci U S A 112:E3431\u2013E3440. https:\/\/doi.org\/10.1073\/pnas.1501835112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13896_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105080","volume":"148","author":"Y-Y Fan","year":"2021","unstructured":"Fan Y-Y, Huo J (2021) A1\/A2 astrocytes in central nervous system injuries and diseases: angels or devils? Neurochem Int 148:105080. https:\/\/doi.org\/10.1016\/j.neuint.2021.105080","journal-title":"Neurochem Int"},{"key":"13896_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1584577","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhang X, Chai Y et al (2025) Astrocyte-mediated inflammatory responses in traumatic brain injury: mechanisms and potential interventions. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1584577","journal-title":"Front Immunol"},{"key":"13896_CR19","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170228","volume":"7","author":"GR Frost","year":"2017","unstructured":"Frost GR, Li Y-M (2017) The role of astrocytes in amyloid production and Alzheimer\u2019s disease. Open Biol 7:170228. https:\/\/doi.org\/10.1098\/rsob.170228","journal-title":"Open Biol"},{"key":"13896_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fnins.2017.00217","volume":"11","author":"A Chiarini","year":"2017","unstructured":"Chiarini A, Armato U, Gardenal E et al (2017) Amyloid \u03b2-exposed human astrocytes overproduce phospho-tau and overrelease it within exosomes, effects suppressed by calcilytic NPS 2143-further implications for Alzheimer\u2019s therapy. Front Neurosci 11:217. https:\/\/doi.org\/10.3389\/fnins.2017.00217","journal-title":"Front Neurosci"},{"key":"13896_CR21","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1038\/s42255-025-01390-y","volume":"7","author":"D Barnett","year":"2025","unstructured":"Barnett D, Zimmer TS, Booraem C et al (2025) Mitochondrial complex III-derived ROS amplify immunometabolic changes in astrocytes and promote dementia pathology. Nat Metab 7:2300\u20132323. https:\/\/doi.org\/10.1038\/s42255-025-01390-y","journal-title":"Nat Metab"},{"key":"13896_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105198","volume":"148","author":"JV Andersen","year":"2021","unstructured":"Andersen JV, Christensen SK, Westi EW et al (2021) Deficient astrocyte metabolism impairs glutamine synthesis and neurotransmitter homeostasis in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis 148:105198. https:\/\/doi.org\/10.1016\/j.nbd.2020.105198","journal-title":"Neurobiol Dis"},{"key":"13896_CR23","doi-asserted-by":"crossref","unstructured":"Boers-Escuder C, Kater MSJ, Zwan MJDVD, et al (2026) Deletion of astrocyte intermediate filaments GFAP and Vimentin enhances protein synthesis and prevents early synaptic and cognitive dysfunction in a mouse model of Alzheimer\u2019s disease. 2026.03.24.713865","DOI":"10.64898\/2026.03.24.713865"},{"key":"13896_CR24","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/glia.23981","volume":"69","author":"T Smit","year":"2021","unstructured":"Smit T, Deshayes NAC, Borchelt DR et al (2021) Reactive astrocytes as treatment targets in Alzheimer\u2019s disease\u2014Systematic review of studies using the APPswePS1dE9 mouse model. Glia 69:1852\u20131881. https:\/\/doi.org\/10.1002\/glia.23981","journal-title":"Glia"},{"key":"13896_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S et al (2022) Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 18:158\u2013172. https:\/\/doi.org\/10.1038\/s41582-021-00616-3","journal-title":"Nat Rev Neurol"},{"key":"13896_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1474-4422(22)00256-3","volume":"21","author":"FK Korley","year":"2022","unstructured":"Korley FK, Jain S, Sun X et al (2022) Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study. Lancet Neurol 21:803\u2013813. https:\/\/doi.org\/10.1016\/S1474-4422(22)00256-3","journal-title":"Lancet Neurol"},{"key":"13896_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.31115","volume":"7","author":"L Papa","year":"2024","unstructured":"Papa L, McKinley WI, Valadka AB et al (2024) Diagnostic performance of GFAP, UCH-L1, and MAP-2 within 30 and 60 minutes of traumatic brain injury. JAMA Netw Open 7:e2431115. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.31115","journal-title":"JAMA Netw Open"},{"key":"13896_CR28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/braincomms\/fcae396","volume":"6","author":"F Leipp","year":"2024","unstructured":"Leipp F, Vialaret J, Mohaupt P et al (2024) Glial fibrillary acidic protein in Alzheimer\u2019s disease: a narrative review. Brain Commun. 6:396. https:\/\/doi.org\/10.1093\/braincomms\/fcae396","journal-title":"Brain Commun."},{"key":"13896_CR29","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","volume":"27","author":"JP Ferrari-Souza","year":"2022","unstructured":"Ferrari-Souza JP, Ferreira PCL, Bellaver B et al (2022) Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer\u2019s disease. Mol Psychiatry 27:4781\u20134789. https:\/\/doi.org\/10.1038\/s41380-022-01716-2","journal-title":"Mol Psychiatry"},{"key":"13896_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02843-5","volume":"20","author":"T Liu","year":"2023","unstructured":"Liu T, Zuo H, Ma D et al (2023) Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer\u2019s disease-associated biomarkers alterations among de novo Parkinson\u2019s disease patients: a prospective cohort study. J Neuroinflammation 20:167. https:\/\/doi.org\/10.1186\/s12974-023-02843-5","journal-title":"J Neuroinflammation"},{"key":"13896_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","volume":"14","author":"S Baiardi","year":"2022","unstructured":"Baiardi S, Quadalti C, Mammana A et al (2022) Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther 14:153. https:\/\/doi.org\/10.1186\/s13195-022-01093-6","journal-title":"Alzheimers Res Ther"},{"key":"13896_CR32","doi-asserted-by":"publisher","first-page":"17145","DOI":"10.1074\/jbc.R115.640359","volume":"290","author":"J Lowery","year":"2015","unstructured":"Lowery J, Kuczmarski ER, Herrmann H, Goldman RD (2015) Intermediate filaments play a pivotal role in regulating cell architecture and function. J Biol Chem 290:17145\u201317153. https:\/\/doi.org\/10.1074\/jbc.R115.640359","journal-title":"J Biol Chem"},{"key":"13896_CR33","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1073\/pnas.86.13.5178","volume":"86","author":"SA Reeves","year":"1989","unstructured":"Reeves SA, Helman LJ, Allison A, Israel MA (1989) Molecular cloning and primary structure of human glial fibrillary acidic protein. Proc Natl Acad Sci U S A 86:5178\u20135182. https:\/\/doi.org\/10.1073\/pnas.86.13.5178","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13896_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/17590914221102065","volume":"14","author":"JV van Asperen","year":"2022","unstructured":"van Asperen JV, Robe PAJT, Hol EM (2022) GFAP alternative splicing and the relevance for disease - a focus on diffuse gliomas. ASN Neuro 14:17590914221102065. https:\/\/doi.org\/10.1177\/17590914221102065","journal-title":"ASN Neuro"},{"key":"13896_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2024.102340","volume":"87","author":"AJEM de Reus","year":"2024","unstructured":"de Reus AJEM, Basak O, Dykstra W et al (2024) GFAP-isoforms in the nervous system: understanding the need for diversity. Curr Opin Cell Biol 87:102340. https:\/\/doi.org\/10.1016\/j.ceb.2024.102340","journal-title":"Curr Opin Cell Biol"},{"key":"13896_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","volume":"38","author":"Z Yang","year":"2015","unstructured":"Yang Z, Wang KKW (2015) Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 38:364\u2013374. https:\/\/doi.org\/10.1016\/j.tins.2015.04.003","journal-title":"Trends Neurosci"},{"key":"13896_CR37","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neurobiolaging.2013.09.035","volume":"35","author":"W Kamphuis","year":"2014","unstructured":"Kamphuis W, Middeldorp J, Kooijman L et al (2014) Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer\u2019s disease. Neurobiol Aging 35:492\u2013510. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.09.035","journal-title":"Neurobiol Aging"},{"key":"13896_CR38","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.bbrc.2018.08.066","volume":"503","author":"B Kim","year":"2018","unstructured":"Kim B, Kim S, Jin MS (2018) Crystal structure of the human glial fibrillary acidic protein 1B domain. Biochem Biophys Res Commun 503:2899\u20132905. https:\/\/doi.org\/10.1016\/j.bbrc.2018.08.066","journal-title":"Biochem Biophys Res Commun"},{"key":"13896_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrm3753","volume":"15","author":"NT Snider","year":"2014","unstructured":"Snider NT, Omary MB (2014) Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat Rev Mol Cell Biol 15:163\u2013177. https:\/\/doi.org\/10.1038\/nrm3753","journal-title":"Nat Rev Mol Cell Biol"},{"key":"13896_CR40","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1016\/S0021-9258(19)39622-X","volume":"265","author":"M Inagaki","year":"1990","unstructured":"Inagaki M, Gonda Y, Nishizawa K et al (1990) Phosphorylation sites linked to glial filament disassembly in vitro locate in a non-alpha-helical head domain. J Biol Chem 265:4722\u20134729","journal-title":"J Biol Chem"},{"key":"13896_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.freeradbiomed.2018.04.007","volume":"120","author":"\u00c1 Viedma-Poyatos","year":"2018","unstructured":"Viedma-Poyatos \u00c1, de Pablo Y, Pekny M, P\u00e9rez-Sala D (2018) The cysteine residue of glial fibrillary acidic protein is a critical target for lipoxidation and required for efficient network organization. Free Radic Biol Med 120:380\u2013394. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.04.007","journal-title":"Free Radic Biol Med"},{"key":"13896_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00300","volume":"8","author":"EP Thelin","year":"2017","unstructured":"Thelin EP, Zeiler FA, Ercole A et al (2017) Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review. Front Neurol 8:300. https:\/\/doi.org\/10.3389\/fneur.2017.00300","journal-title":"Front Neurol"},{"key":"13896_CR43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0165-0270(94)90011-6","volume":"51","author":"LE Rosengren","year":"1994","unstructured":"Rosengren LE, Wikkels\u00f8 C, Hagberg L (1994) A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 51:197\u2013204. https:\/\/doi.org\/10.1016\/0165-0270(94)90011-6","journal-title":"J Neurosci Methods"},{"key":"13896_CR44","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78:1471\u20131483. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671","journal-title":"JAMA Neurol"},{"key":"13896_CR45","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1515\/cclm-2023-1256","volume":"62","author":"B Fazeli","year":"2024","unstructured":"Fazeli B, G\u00f3mez de San Jos\u00e9 N, Jesse S et al (2024) Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays. Clin Chem Lab Med 62:1591\u20131601. https:\/\/doi.org\/10.1515\/cclm-2023-1256","journal-title":"Clin Chem Lab Med"},{"key":"13896_CR46","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1515\/cclm-2025-0093","volume":"63","author":"L Agnello","year":"2025","unstructured":"Agnello L, Gambino CM, Ciaccio AM et al (2025) Establishing sex- and age-related reference intervals of serum glial fibrillary acid protein measured by the fully automated Lumipulse system. Clin Chem Lab Med 63:1402\u20131408. https:\/\/doi.org\/10.1515\/cclm-2025-0093","journal-title":"Clin Chem Lab Med"},{"key":"13896_CR47","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1515\/cclm-2025-0870","volume":"63","author":"B Arslan","year":"2025","unstructured":"Arslan B, Andreasson U, Rembeza E et al (2025) Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation. Clin Chem Lab Med (CCLM) 63:2522\u20132535. https:\/\/doi.org\/10.1515\/cclm-2025-0870","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"13896_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16226","volume":"169","author":"D Gogishvili","year":"2025","unstructured":"Gogishvili D, Honey MIJ, Verberk IMW et al (2025) The GFAP proteoform puzzle: how to advance GFAP as a fluid biomarker in neurological diseases. J Neurochem 169:e16226. https:\/\/doi.org\/10.1111\/jnc.16226","journal-title":"J Neurochem"},{"key":"13896_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14222520","volume":"14","author":"J Kamada","year":"2024","unstructured":"Kamada J, Hamanaka T, Oshimo A et al (2024) Glial fibrillary acidic protein\u2019s usefulness as an astrocyte biomarker using the fully automated LUMIPULSE\u00ae system. Diagn (Basel) 14:2520. https:\/\/doi.org\/10.3390\/diagnostics14222520","journal-title":"Diagn (Basel)"},{"key":"13896_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/1759091420949680","volume":"12","author":"A Messing","year":"2020","unstructured":"Messing A, Brenner M (2020) GFAP at 50. ASN Neuro 12:1759091420949680. https:\/\/doi.org\/10.1177\/1759091420949680","journal-title":"ASN Neuro"},{"key":"13896_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00846-9","volume":"20","author":"W Youn","year":"2025","unstructured":"Youn W, Yun M, Lee CJ, Sch\u00f6ll M (2025) Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases. Mol Neurodegener 20:54. https:\/\/doi.org\/10.1186\/s13024-025-00846-9","journal-title":"Mol Neurodegener"},{"key":"13896_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.01054","author":"NA Huebschmann","year":"2020","unstructured":"Huebschmann NA, Luoto TM, Karr JE et al (2020) Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.01054","journal-title":"Front Neurol"},{"key":"13896_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neumar.2025.100038","volume":"2","author":"J Marksteiner","year":"2025","unstructured":"Marksteiner J, Humpel C (2025) Glial fibrillary acidic protein as a biomarker for diagnosis of Alzheimer\u2019s disease in cerebrospinal fluid, plasma and saliva measured with Lumipulse technology: a narrative review. NeuroMarkers 2:100038. https:\/\/doi.org\/10.1016\/j.neumar.2025.100038","journal-title":"NeuroMarkers"},{"key":"13896_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1682198","author":"J Tortosa-Carreres","year":"2025","unstructured":"Tortosa-Carreres J, Cubas-N\u00fa\u00f1ez L, Castillo-Villalba J et al (2025) Cross-platform analytical assessment of serum GFAP quantification in multiple sclerosis: SIMOA versus two automated immunoassays. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2025.1682198","journal-title":"Front Neurol"},{"key":"13896_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2025.e00455","volume":"44","author":"M Anwar","year":"2025","unstructured":"Anwar M, Renu K, Singh AK et al (2025) Impact of hemolysis on the levels of proteins associated with aging and age-related neurodegenerative diseases in a multicentric clinical research. Pract Lab Med 44:e00455. https:\/\/doi.org\/10.1016\/j.plabm.2025.e00455","journal-title":"Pract Lab Med"},{"key":"13896_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205323","volume":"13","author":"B Breitling","year":"2018","unstructured":"Breitling B, Brunkhorst R, Verhoff M, Foerch C (2018) Post-mortem serum concentrations of GFAP correlate with agony time but do not indicate a primary cerebral cause of death. PLoS ONE 13:e0205323. https:\/\/doi.org\/10.1371\/journal.pone.0205323","journal-title":"PLoS ONE"},{"key":"13896_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1627405","volume":"16","author":"B Evertsson","year":"2025","unstructured":"Evertsson B, Remahl IN, Hietala MA, Finn A (2025) Glial fibrillary acidic protein in cerebrospinal fluid in humans is sensitive to various pre-analytical conditions: possible explanation and solution. Front Neurol 16:1627405. https:\/\/doi.org\/10.3389\/fneur.2025.1627405","journal-title":"Front Neurol"},{"key":"13896_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04130-2","volume":"26","author":"T Axelsson","year":"2025","unstructured":"Axelsson T, Zetterberg H, Blennow K et al (2025) Plasma concentrations of neurofilament light, p-Tau231 and glial fibrillary acidic protein are elevated in patients with chronic kidney disease and correlate with measured glomerular filtration rate. BMC Nephrol 26:231. https:\/\/doi.org\/10.1186\/s12882-025-04130-2","journal-title":"BMC Nephrol"},{"key":"13896_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70502","volume":"21","author":"M Fern\u00e1ndez-Matarrubia","year":"2025","unstructured":"Fern\u00e1ndez-Matarrubia M, Valera-Barrero A, Renuncio-Garc\u00eda M et al (2025) Early microglial and astrocyte reactivity in preclinical Alzheimer\u2019s disease. Alzheimers Dement 21:e70502. https:\/\/doi.org\/10.1002\/alz.70502","journal-title":"Alzheimers Dement"},{"key":"13896_CR60","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41380-022-01511-z","volume":"27","author":"EG Knox","year":"2022","unstructured":"Knox EG, Aburto MR, Clarke G et al (2022) The blood-brain barrier in aging and neurodegeneration. Mol Psychiatry 27:2659\u20132673. https:\/\/doi.org\/10.1038\/s41380-022-01511-z","journal-title":"Mol Psychiatry"},{"key":"13896_CR61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/ageing\/afaa194","volume":"50","author":"LJ Blank","year":"2020","unstructured":"Blank LJ, Acton EK, Thibault D, Willis AW (2020) Neurodegenerative disease is associated with increased incidence of epilepsy: a population based study of older adults. Age Ageing 50:205\u2013212. https:\/\/doi.org\/10.1093\/ageing\/afaa194","journal-title":"Age Ageing"},{"key":"13896_CR62","doi-asserted-by":"publisher","first-page":"e240001","DOI":"10.20900\/agmr.20240001","volume":"6","author":"AL Kehrer-Dunlap","year":"2024","unstructured":"Kehrer-Dunlap AL, Keleman AA, Bollinger RM, Stark SL (2024) Falls and Alzheimer Disease. Adv Geriatr Med Res. 6:e240001. https:\/\/doi.org\/10.20900\/agmr.20240001","journal-title":"Adv Geriatr Med Res."},{"key":"13896_CR63","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr.","year":"2011","unstructured":"Jack CR Jr., Albert MS, Knopman DS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:257\u2013262. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.004","journal-title":"Alzheimers Dement"},{"key":"13896_CR64","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel H, Cummings J, Blennow K et al (2021) Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 17:580\u2013589. https:\/\/doi.org\/10.1038\/s41582-021-00520-w","journal-title":"Nat Rev Neurol"},{"key":"13896_CR65","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S et al (2019) Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis 67:481\u2013488. https:\/\/doi.org\/10.3233\/JAD-180325","journal-title":"J Alzheimers Dis"},{"key":"13896_CR66","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40035-021-00275-w","volume":"10","author":"N Zhu","year":"2021","unstructured":"Zhu N, Santos-Santos M, Ill\u00e1n-Gala I et al (2021) Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Transl Neurodegener 10:50. https:\/\/doi.org\/10.1186\/s40035-021-00275-w","journal-title":"Transl Neurodegener"},{"key":"13896_CR67","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s00406-025-02013-z","volume":"275","author":"C Kurz","year":"2025","unstructured":"Kurz C, Carli L, G\u00fcrsel S\u00dc et al (2025) Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer\u2019s disease and corticobasal syndrome. Eur Arch Psychiatry Clin Neurosci 275:2255\u20132273. https:\/\/doi.org\/10.1007\/s00406-025-02013-z","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"13896_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100724","volume":"6","author":"VR Varma","year":"2025","unstructured":"Varma VR, An Y, Kac PR et al (2025) Longitudinal progression of blood biomarkers reveals a key role of reactive astrocytosis in preclinical Alzheimer\u2019s disease. Med 6:100724. https:\/\/doi.org\/10.1016\/j.medj.2025.100724","journal-title":"Med"},{"key":"13896_CR69","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/acn3.51652","volume":"9","author":"MM Gonzales","year":"2022","unstructured":"Gonzales MM, Wiedner C, Wang C-P et al (2022) A population-based meta-analysis of circulating GFAP for cognition and dementia risk. Ann Clin Transl Neurol 9:1574\u20131585. https:\/\/doi.org\/10.1002\/acn3.51652","journal-title":"Ann Clin Transl Neurol"},{"key":"13896_CR70","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","volume":"69","author":"X-N Shen","year":"2023","unstructured":"Shen X-N, Huang S-Y, Cui M et al (2023) Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: Relationship to other biomarkers, differential diagnosis, and prediction of clinical progression. Clin Chem 69:411\u2013421. https:\/\/doi.org\/10.1093\/clinchem\/hvad018","journal-title":"Clin Chem"},{"key":"13896_CR71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J et al (2021) Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther 13:68. https:\/\/doi.org\/10.1186\/s13195-021-00804-9","journal-title":"Alzheimers Res Ther"},{"key":"13896_CR72","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cells12091309","volume":"12","author":"KY Kim","year":"2023","unstructured":"Kim KY, Shin KY, Chang K-A (2023) GFAP as a potential biomarker for Alzheimer\u2019s disease: A systematic review and meta-analysis. Cells 12:1309. https:\/\/doi.org\/10.3390\/cells12091309","journal-title":"Cells"},{"key":"13896_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/alz70856_105473","volume":"21","author":"D Bali","year":"2026","unstructured":"Bali D, Janelidze S, Salvad\u00f3 G et al (2026) Can longitudinal measures of plasma biomarkers track disease progression in early Alzheimer\u00b4s disease? Alzheimers Dement 21:e105473. https:\/\/doi.org\/10.1002\/alz70856_105473","journal-title":"Alzheimers Dement"},{"key":"13896_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01684-z","volume":"17","author":"C Boccalini","year":"2025","unstructured":"Boccalini C, Peretti DE, Scheffler M et al (2025) Sex differences in the association of Alzheimer\u2019s disease biomarkers and cognition in a multicenter memory clinic study. Alzheimers Res Ther 17:46. https:\/\/doi.org\/10.1186\/s13195-025-01684-z","journal-title":"Alzheimers Res Ther"},{"key":"13896_CR75","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R et al (2021) Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144:3505\u20133516. https:\/\/doi.org\/10.1093\/brain\/awab223","journal-title":"Brain"},{"key":"13896_CR76","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1093\/brain\/awae211","volume":"147","author":"DE Peretti","year":"2024","unstructured":"Peretti DE, Boccalini C, Ribaldi F et al (2024) Association of glial fibrillary acid protein, Alzheimer\u2019s disease pathology and cognitive decline. Brain 147:4094\u20134104. https:\/\/doi.org\/10.1093\/brain\/awae211","journal-title":"Brain"},{"key":"13896_CR77","doi-asserted-by":"publisher","first-page":"15576","DOI":"10.1007\/s12035-025-05219-3","volume":"62","author":"EMS Bandara","year":"2025","unstructured":"Bandara EMS, Asih PR, Pedrini S et al (2025) The role of glial fibrillary acidic protein in the neuropathology of Alzheimer\u2019s disease and its potential as a blood biomarker for early diagnosis and progression. Mol Neurobiol 62:15576\u201315608. https:\/\/doi.org\/10.1007\/s12035-025-05219-3","journal-title":"Mol Neurobiol"},{"key":"13896_CR78","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13195-014-0073-2","volume":"6","author":"WS Kim","year":"2014","unstructured":"Kim WS, K\u00e5gedal K, Halliday GM (2014) Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther 6:73. https:\/\/doi.org\/10.1186\/s13195-014-0073-2","journal-title":"Alzheimers Res Ther"},{"key":"13896_CR79","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1093\/brain\/awae203","volume":"147","author":"L Barba","year":"2024","unstructured":"Barba L, Abu-Rumeileh S, Barthel H et al (2024) Clinical and diagnostic implications of Alzheimer\u2019s disease copathology in Lewy body disease. Brain 147:3325\u20133343. https:\/\/doi.org\/10.1093\/brain\/awae203","journal-title":"Brain"},{"key":"13896_CR80","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","volume":"93","author":"L Chouliaras","year":"2022","unstructured":"Chouliaras L, Thomas A, Malpetti M et al (2022) Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 93:651\u2013658. https:\/\/doi.org\/10.1136\/jnnp-2021-327788","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13896_CR81","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209418","volume":"102","author":"K Bolsewig","year":"2024","unstructured":"Bolsewig K, van Unnik AAJM, Blujdea ER et al (2024) Association of plasma amyloid, P-Tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with Lewy bodies. Neurology 102:e209418. https:\/\/doi.org\/10.1212\/WNL.0000000000209418","journal-title":"Neurology"},{"key":"13896_CR82","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/acn3.51768","volume":"10","author":"KAQ Cousins","year":"2023","unstructured":"Cousins KAQ, Irwin DJ, Chen-Plotkin A et al (2023) Plasma GFAP associates with secondary Alzheimer\u2019s pathology in Lewy body disease. Ann Clin Transl Neurol 10:802\u2013813. https:\/\/doi.org\/10.1002\/acn3.51768","journal-title":"Ann Clin Transl Neurol"},{"key":"13896_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/alz.091713","volume":"20","author":"JJ Alam","year":"2024","unstructured":"Alam JJ, Koel-Simmerlink MJ, Conway J et al (2024) Neflamapimod treatment reduces plasma glial fibriallary acidic protein levels in patients with pure dementia with Lewy bodies (DLB). Alzheimers Dement 20:e091713. https:\/\/doi.org\/10.1002\/alz.091713","journal-title":"Alzheimers Dement"},{"key":"13896_CR84","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/biom15040473","volume":"15","author":"PA Erichsen","year":"2025","unstructured":"Erichsen PA, Henriksen EE, Nielsen JE et al (2025) Immunological fluid biomarkers in Frontotemporal Dementia: a systematic review. Biomolecules 15:473. https:\/\/doi.org\/10.3390\/biom15040473","journal-title":"Biomolecules"},{"key":"13896_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111838","volume":"25","author":"I Liampas","year":"2024","unstructured":"Liampas I, Kyriakoulopoulou P, Karakoida V et al (2024) Blood-based biomarkers in Frontotemporal Dementia: a narrative review. Int J Mol Sci 25:11838. https:\/\/doi.org\/10.3390\/ijms252111838","journal-title":"Int J Mol Sci"},{"key":"13896_CR86","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3233\/JAD-200608","volume":"77","author":"A Benussi","year":"2020","unstructured":"Benussi A, Ashton NJ, Karikari TK et al (2020) Serum glial fibrillary acidic protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration. J Alzheimers Dis 77:1129\u20131141. https:\/\/doi.org\/10.3233\/JAD-200608","journal-title":"J Alzheimers Dis"},{"key":"13896_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.118784","volume":"558","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wang Y, Tao Q et al (2024) Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: a multicenter cohort study. Clin Chim Acta 558:118784. https:\/\/doi.org\/10.1016\/j.cca.2024.118784","journal-title":"Clin Chim Acta"},{"key":"13896_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00821-4","volume":"20","author":"U Sheth","year":"2025","unstructured":"Sheth U, \u00d6ijerstedt L, Heckman MG et al (2025) Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders. Mol Neurodegener 20:30. https:\/\/doi.org\/10.1186\/s13024-025-00821-4","journal-title":"Mol Neurodegener"},{"key":"13896_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0562-4","volume":"12","author":"S Abu-Rumeileh","year":"2019","unstructured":"Abu-Rumeileh S, Steinacker P, Polischi B et al (2019) CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther 12:2. https:\/\/doi.org\/10.1186\/s13195-019-0562-4","journal-title":"Alzheimers Res Ther"},{"key":"13896_CR90","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JAD-220318","volume":"90","author":"K Bolsewig","year":"2022","unstructured":"Bolsewig K, Hok-A-Hin YS, Sepe FN et al (2022) A combination of neurofilament light, glial fibrillary acidic protein, and neuronal pentraxin-2 discriminates between frontotemporal dementia and other dementias. J Alzheimers Dis 90:363\u2013380. https:\/\/doi.org\/10.3233\/JAD-220318","journal-title":"J Alzheimers Dis"},{"key":"13896_CR91","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","volume":"136","author":"A Ishiki","year":"2016","unstructured":"Ishiki A, Kamada M, Kawamura Y et al (2016) Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem 136:258\u2013261. https:\/\/doi.org\/10.1111\/jnc.13399","journal-title":"J Neurochem"},{"key":"13896_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01647-w","volume":"16","author":"P Mohaupt","year":"2024","unstructured":"Mohaupt P, Kindermans J, Vialaret J et al (2024) Blood-based biomarkers and plasma A\u03b2 assays in the differential diagnosis of Alzheimer\u2019s disease and behavioral-variant frontotemporal dementia. Alzheimers Res Ther 16:279. https:\/\/doi.org\/10.1186\/s13195-024-01647-w","journal-title":"Alzheimers Res Ther"},{"key":"13896_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031231","volume":"26","author":"E G\u00f3mez-Tortosa","year":"2025","unstructured":"G\u00f3mez-Tortosa E, Ag\u00fcero-Rabes P, Ruiz-Gonz\u00e1lez A et al (2025) Plasma biomarkers in the distinction of Alzheimer\u2019s disease and frontotemporal dementia. Int J Mol Sci 26:1231. https:\/\/doi.org\/10.3390\/ijms26031231","journal-title":"Int J Mol Sci"},{"key":"13896_CR94","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","volume":"91","author":"C Heller","year":"2020","unstructured":"Heller C, Foiani MS, Moore K et al (2020) Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry 91:263\u2013270. https:\/\/doi.org\/10.1136\/jnnp-2019-321954","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13896_CR95","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.09.579529","author":"J Hsiao-Nakamoto","year":"2024","unstructured":"Hsiao-Nakamoto J, Chiu C-L, VandeVrede L et al (2024) Alterations in lysosomal, glial and neurodegenerative biomarkers in patients with sporadic and genetic forms of frontotemporal dementia. BioRxiv. https:\/\/doi.org\/10.1101\/2024.02.09.579529","journal-title":"BioRxiv"},{"key":"13896_CR96","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41591-024-02973-0","volume":"30","author":"J Sevigny","year":"2024","unstructured":"Sevigny J, Uspenskaya O, Heckman LD et al (2024) Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1\/2 trial interim results. Nat Med 30:1406\u20131415. https:\/\/doi.org\/10.1038\/s41591-024-02973-0","journal-title":"Nat Med"},{"key":"13896_CR97","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/jnnp-2021-326487","volume":"92","author":"K Katisko","year":"2021","unstructured":"Katisko K, Cajanus A, Huber N et al (2021) GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry 92:1305\u20131312. https:\/\/doi.org\/10.1136\/jnnp-2021-326487","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13896_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2024-001007","volume":"7","author":"SCM de Boer","year":"2025","unstructured":"de Boer SCM, Fenoglio C, Arighi A et al (2025) Serum neurofilament light is superior to glial fibrillary acidic protein to distinguish sporadic frontotemporal dementia from late-onset primary psychiatric disorders: a retrospective DIPPA-FTD study. BMJ Neurol Open 7:e001007. https:\/\/doi.org\/10.1136\/bmjno-2024-001007","journal-title":"BMJ Neurol Open"},{"key":"13896_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123291","volume":"467","author":"D Eratne","year":"2024","unstructured":"Eratne D, Kang MJY, Lewis C et al (2024) Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders. J Neurol Sci 467:123291. https:\/\/doi.org\/10.1016\/j.jns.2024.123291","journal-title":"J Neurol Sci"},{"key":"13896_CR100","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3233\/JAD-190378","volume":"74","author":"C Marelli","year":"2020","unstructured":"Marelli C, Hourregue C, Gutierrez L-A et al (2020) Cerebrospinal fluid and plasma biomarkers do not differ in the presenile and late-onset behavioral variants of frontotemporal dementia. J Alzheimers Dis 74:903\u2013911. https:\/\/doi.org\/10.3233\/JAD-190378","journal-title":"J Alzheimers Dis"},{"key":"13896_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/srep40779","volume":"7","author":"R Zhu","year":"2017","unstructured":"Zhu R, Xie C, Hu P, Wang K (2017) Clinical variations in Parkinson\u2019s disease patients with or without REM sleep behaviour disorder: a meta-analysis. Sci Rep 7:40779. https:\/\/doi.org\/10.1038\/srep40779","journal-title":"Sci Rep"},{"key":"13896_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119975","volume":"565","author":"Y Chen","year":"2025","unstructured":"Chen Y, Huang J, Li Y et al (2025) Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson\u2019s disease. Clin Chim Acta 565:119975. https:\/\/doi.org\/10.1016\/j.cca.2024.119975","journal-title":"Clin Chim Acta"},{"key":"13896_CR103","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","volume":"9","author":"Y Tang","year":"2023","unstructured":"Tang Y, Han L, Li S et al (2023) Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia. npj Parkinsons Dis. 9:23. https:\/\/doi.org\/10.1038\/s41531-023-00447-7","journal-title":"npj Parkinsons Dis."},{"key":"13896_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03120-1","volume":"21","author":"J Lin","year":"2023","unstructured":"Lin J, Ou R, Li C et al (2023) Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson\u2019s disease: a prospective cohort study. BMC Med 21:420. https:\/\/doi.org\/10.1186\/s12916-023-03120-1","journal-title":"BMC Med"},{"key":"13896_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32480-0","volume":"13","author":"P Youssef","year":"2023","unstructured":"Youssef P, Hughes L, Kim WS et al (2023) Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson\u2019s disease biomarkers using multiplexed single molecule counting. Sci Rep 13:5217. https:\/\/doi.org\/10.1038\/s41598-023-32480-0","journal-title":"Sci Rep"},{"key":"13896_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00664-8","volume":"10","author":"N Che","year":"2024","unstructured":"Che N, Ou R, Li C et al (2024) Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson\u2019s disease. NPJ Parkinsons Dis 10:48. https:\/\/doi.org\/10.1038\/s41531-024-00664-8","journal-title":"NPJ Parkinsons Dis"},{"key":"13896_CR107","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/jnc.15780","volume":"165","author":"X Teng","year":"2023","unstructured":"Teng X, Mao S, Wu H et al (2023) The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson\u2019s disease. J Neurochem 165:268\u2013276. https:\/\/doi.org\/10.1111\/jnc.15780","journal-title":"J Neurochem"},{"key":"13896_CR108","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/psyg.13088","volume":"24","author":"P Yin","year":"2024","unstructured":"Yin P, Niu X, Guan C et al (2024) Relationship between increased serum neurofilament light chain and glial fibrillary acidic protein levels with non-motor symptoms in patients with Parkinson\u2019s disease. Psychogeriatrics 24:415\u2013425. https:\/\/doi.org\/10.1111\/psyg.13088","journal-title":"Psychogeriatrics"},{"key":"13896_CR109","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1007\/s00415-024-12669-7","volume":"271","author":"A Pilotto","year":"2024","unstructured":"Pilotto A, Ashton NJ, Lupini A et al (2024) Plasma NfL, GFAP, amyloid, and p-tau species as prognostic biomarkers in Parkinson\u2019s disease. J Neurol 271:7537\u20137546. https:\/\/doi.org\/10.1007\/s00415-024-12669-7","journal-title":"J Neurol"},{"issue":"25","key":"13896_CR110","doi-asserted-by":"publisher","first-page":"01060","DOI":"10.1016\/j.acra.2025.11.008","volume":"S1076\u20136332","author":"Q Li","year":"2025","unstructured":"Li Q, Bai X, Zhang S et al (2025) The association of enlarged perivascular space with cerebrospinal fluid GFAP in early parkinson\u2019s disease. Acad Radiol S1076\u20136332(25):01060\u201301068. https:\/\/doi.org\/10.1016\/j.acra.2025.11.008","journal-title":"Acad Radiol"},{"key":"13896_CR111","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70111","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang J, Ning F et al (2024) Longitudinal correlation of cerebrospinal fluid GFAP and the progression of cognition decline in different clinical subtypes of Parkinson\u2019s disease. Clin Transl Sci 17:e70111. https:\/\/doi.org\/10.1111\/cts.70111","journal-title":"Clin Transl Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13896-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:09:46Z","timestamp":1781370586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13896-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["13896"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13896-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no competing or financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"351"}}